FDA Grants Priority Review for Avalglucosidase Alfa, a Potential New Therapy for Pompe Disease

PARIS– November 18, 2020 - The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for avalglucosidase alfa for long-term enzyme replacement therapy for the treatment of patients...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials